- ISIN
- US92840H2022
- CUSIP
- 92840H202
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- May 6, 2016
Highlights
- Market Cap
- $8.46M
- Enterprise Value
- -$20.49M
- EPS (TTM)
- -$1.80
- Total Revenue (TTM)
- $1.27M
- Gross Profit (TTM)
- $522.00K
- EBITDA (TTM)
- -$68.97M
- Year Range
- $0.20 - $5.14
- Target Price
- $0.95
- ROA (TTM)
- -143.49%
- ROE (TTM)
- -196.19%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
VTGN Performance Chart
VistaGen Therapeutics, Inc. (VTGN) is down 61.0% since the beginning of the year. At $0 per share, VTGN is trading 95.0% below its 52-week high of $5. Investors who bought $1,000 worth of VTGN shares 5 years ago would now be looking at an investment worth $3.
Loading charts...
Returns By Period
VistaGen Therapeutics, Inc. (VTGN) has returned -61.02% so far this year and -89.16% over the past 12 months. Over the last ten years, VTGN has returned -45.62% per year, falling short of the S&P 500 Index benchmark, which averaged 13.41% annually.
VistaGen Therapeutics, Inc.
- 1D
- 3.53%
- 1M
- -55.22%
- 6M
- -60.92%
- YTD
- -61.02%
- 1Y
- -89.16%
- 3Y*
- -46.66%
- 5Y*
- -69.19%
- 10Y*
- -45.62%
Benchmark (S&P 500 Index)
- 1D
- 0.42%
- 1M
- 1.94%
- 6M
- 8.74%
- YTD
- 10.66%
- 1Y
- 21.02%
- 3Y*
- 19.50%
- 5Y*
- 11.63%
- 10Y*
- 13.41%
VTGN Monthly Returns History
Based on dividend-adjusted daily data since May 6, 2016, VTGN's average daily return is +0.22%, while the average monthly return is +0.60%. At this rate, an investment would double in approximately 9.7 years.
Historically, 46% of months were positive and 54% were negative. The best month was Aug 2023 with a return of +192.9%, while the worst month was Dec 2025 at -86.5%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 4 months.
On a daily basis, VTGN closed higher 44% of trading days. The best single day was Aug 7, 2023 with a return of +676.8%, while the worst single day was Jul 22, 2022 at -86.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -15.67% | 4.98% | -2.47% | 7.33% | 2.71% | -64.13% | 14.16% | -61.02% | |||||
| 2025 | -2.03% | -6.57% | -7.41% | -6.40% | 10.26% | -22.48% | 43.50% | 16.38% | 6.29% | 10.99% | 24.37% | -86.49% | -77.56% |
| 2024 | -7.00% | 6.90% | 3.33% | -8.52% | -20.08% | -9.84% | -1.44% | 1.75% | -13.75% | 2.33% | -7.79% | 3.87% | -42.61% |
| 2023 | 151.26% | -32.15% | -28.99% | 12.27% | 1.50% | -56.13% | -2.67% | 192.86% | -1.69% | -39.31% | 12.89% | 43.18% | 66.34% |
| 2022 | -16.41% | -14.11% | -11.43% | 2.42% | -9.45% | -23.48% | -83.74% | 28.58% | -17.34% | -12.82% | 4.15% | -25.42% | -94.72% |
| 2021 | 9.28% | 16.51% | -13.77% | 18.78% | 2.37% | 21.62% | -15.56% | 14.29% | -9.87% | -16.42% | -15.72% | 1.04% | 0.52% |
Benchmark Metrics
VistaGen Therapeutics, Inc. has an annualized alpha of 45.19%, beta of 1.34, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since May 06, 2016.
- This stock participated in 203.86% of S&P 500 Index downside but only -51.02% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 45.19%
- Beta
- 1.34
- R²
- 0.01
- Upside Capture
- -51.02%
- Downside Capture
- 203.86%
Return for Risk
Risk / Return Rank
VTGN ranks 14 for risk / return — in the bottom 14% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for VistaGen Therapeutics, Inc. (VTGN) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| VTGN | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.32 | ||
| Sortino ratioReturn per unit of downside risk | -2.79 | ||
| Omega ratioGain probability vs. loss probability | 0.90 | 1.30 | -0.41 |
| Calmar ratioReturn relative to maximum drawdown | -0.94 | 2.28 | -3.21 |
| Martin ratioReturn relative to average drawdown | -1.36 | 9.88 | -11.24 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the VistaGen Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the VistaGen Therapeutics, Inc. was 99.89%, occurring on Jun 30, 2026. The portfolio has not yet recovered.
The current VistaGen Therapeutics, Inc. drawdown is 99.88%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -99.89%Jun 2026 | 10y 1mo | — | 10y 2moMay 2016 - now |
Drawdown Indicators
| VTGN | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.89% | -56.78% | -43.11% |
Max Drawdown (1Y)Largest decline over 1 year | -95.39% | -9.10% | -86.29% |
Max Drawdown (3Y)Largest decline over 3 years | -98.27% | -18.90% | -79.37% |
Max Drawdown (5Y)Largest decline over 5 years | -99.76% | -25.43% | -74.33% |
Max Drawdown (10Y)Largest decline over 10 years | -99.83% | -33.92% | -65.91% |
Current DrawdownCurrent decline from peak | -99.88% | -0.45% | -99.43% |
Average DrawdownAverage peak-to-trough decline | -84.55% | -10.71% | -73.84% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 65.76% | 2.09% | +63.67% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of VistaGen Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how VistaGen Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for VTGN relative to other companies in the Biotechnology industry. Currently, VTGN has a P/S ratio of 7.9. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for VTGN in comparison with other companies in the Biotechnology industry. Currently, VTGN has a P/B value of 0.3. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with VTGN
Add VistaGen Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with VTGN